Retatrutide meets primary endpoints in TRIUMPH-2 and TRIUMPH-3

Lilly reported that retatrutide met the primary endpoint in two more Phase 3 obesity trials: TRIUMPH-2 in adults with obesity and type 2 diabetes, and TRIUMPH-3 in adults with severe obesity and cardiovascular disease. At 80 weeks the 12 mg dose cut body weight by 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3, against placebo declines of 4.0% and 3.2%. Lilly still plans a BLA submission in the first quarter of 2027.

• TRIUMPH-2 (type 2 diabetes): 12 mg -20.8% vs -4.0% placebo at 80 weeks
• TRIUMPH-3 (severe obesity with CVD): 12 mg -22.6% vs -3.2% placebo at 80 weeks
• TRIUMPH-3 9 mg: -21.6%
• BLA submission planned for Q1 2027